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Abstract
Background: Rapid tranquillisation is used when control of agitation, aggression or excitement is required.
Throughout the UK there is no consensus over the choice of drugs to be used as first line treatment. The NICE
guideline on the management of violent behaviour involving psychiatric inpatients conducted a systematic
examination of the literature relating to the effectiveness and safety of rapid tranquillisation (NICE, 2005).
This paper presents the key findings from that review and key guideline recommendations generated, and
discusses the implications for practice of more recent research and information.
Aims: To examine the evidence on the efficacy and safety of medications used for rapid tranquillisation in
inpatient psychiatric settings.
Method: Systematic review of current guidelines and phase III randomised, controlled trials of medication
used for rapid tranquillisation. Formal consensus methods were used to generate clinically relevant
recommendations to support safe and effective prescribing of rapid tranquillisation in the development of
a NICE guideline.
Findings: There is a lack of high quality clinical trial evidence in the UK and therefore a ‘gold standard’
medication regime for rapid tranquillisation has not been established.
Rapid tranquillisation and clinical practice: The NICE guideline produced 35 recommendations on rapid
tranquillisation practice for the UK, with the primary aim of calming the service user to enable the use of
psychosocial techniques.
Conclusions and implications for clinical practice: Further UK specific research is urgently needed that
provides the clinician with a hierarchy of options for the clinical practice of rapid tranquillisation.
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INTRODUCTION
Rapid tranquillisation or urgent sedation
(Broadstock, 2001), is used in situations requir-
ing the rapid control of agitation, aggression or
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excitement in adult psychiatric inpatients where
de-escalation techniques have not proved suffi-
cient in themselves. Although the use of high
dose antipsychotics for this purpose has been
criticised by several inquiries (Royal College
of Psychiatrists, 1997), expert clinician opinion,
has in exceptional circumstances, supported
prescribing outside the dose limits stated in the
British National Formulary (BNF) in order to
achieve rapid tranquillisation.
Very few randomised controlled trials have
been conducted which examine the safety and
efficacy of medicines that are used for rapid
tranquilisation. In recent years there has been a
general reduction in the range of doses that
are used. This shift in practice coincides with
the changes in the stated aim of rapid tranquilli-
sation over recent years: to induce a state of
calm, rather than sleep (Cunnane, 1994; Beer
et al., 2001; Burgess, 1997).
A systematic review on rapid tranquillisa-
tion was conducted for the National Institute
of Health and Clinical Excellence (NICE)
guideline on the short-term management of
disturbed/violent behaviour in psychiatric in-
patient settings and emergency departments.
This paper presents the key results of that review,
notes more recent research and changes in med-
ication Summary of Product Characteristics
(SPC). The implications for practice are dis-
cussed in the light of the key recommendations
for rapid tranquillisation from the guideline.
BACKGROUND
Benzodiazepines and antipsychotics either alone
or in combination are commonly used in the
UK for rapid tranquillisation. The oral route is
preferred, but when refused drugs are adminis-
tered parenterally. When diazepam is adminis-
tered intramuscularly its absorption is slow and
erratic and with repeated doses is associated
with prolonged sedation. Lorazepam, has a
shorter elimination half-life than many other
benzodiazepines, which may limit the risks asso-
ciated with dose accumulation. All the benzo-
diazepines carry a risk of respiratory depression
when used in high doses or in combination
with other hypnosedatives (Broadstock, 2001).
Although antipsychotics are considered to be
a second line treatment they can be used as first
line where benzodiazepines are contra-indicated
or have been ineffective. Conventional antipsy-
chotics have a greater propensity to cause extra-
pyramidal side effects (EPS) than the atypical
antipsychotics.
In some areas it is common practice to co-
administer both a benzodiazepine and antipsy-
chotic together. This is thought preferable by
some clinicians who consider the practice enables
behavioural control to be achieved without the
need for resorting to higher doses of antipsycho-
tics (Holmes et al., 2001).
The two main areas of concern when using
antipsychotics for rapid tranquillisation are the
induction of extrapyramidal side effects and
adverse cardiac events (see Box 1). Extrapyrami-
dal side effects are mostly associated with conven-
tional antipsychotics. Side effects such as dystonia
and akathisia are distressing and unpleasant for the
service user. Experiencing these at the time of
initial contact with psychiatric services may
adversely affect a patient’s preparedness to access
either treatments or services. The availability of
atypical antipsychotic drugs provides some hope
that these adverse effects can be avoided.
This paper presents the relevant findings
of the evidence review used to generate the
NICE guideline recommendations for the prac-
tice of rapid tranquillisation for the short term
management of violence in psychiatric inpati-
ents and emergency departments. Key studies
published since the review was conducted,
changes in the SPC for haloperidol and the
implications for the current recommendations
with reference to the UK context are discussed.
REVIEW METHODS
Aim of the review
To examine the evidence on the efficacy and
safety of medications currently used for rapid
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tranquillisation within psychiatric inpatient set-
tings in the UK.
Inclusion criteria
Systematic reviews through to Phase III rando-
mised controlled trials. All adults 16 years and
over in inpatient psychiatric settings applicable
to the UK.
Exclusion criteria
Those with organic brain disorders or progress-
ive neurological dysfunction, learning disability
or dual diagnosis.
Types of outcome
Efficacy and safety of the various medications
used for rapid tranquillisation
Searching, critical appraisal and
data extraction
The methods adopted in this review are those
outlined in Eccles & Mason (1998) and in the
NICE Technical Manual (2004). An exten-
sive search of the literature was undertaken.
Searches were run from 19692003. All
major databases including Medline, CINAHL,
PSYCHINFO, grey literature databases SIGLE
and HMIC were searched. For a complete list
of databases searched and search terms used,
including those used by the Royal College of
Psychiatrists see Royal College of Nursing
(2005). Searches were not limited by study
design, or to English language citations. Hand
searching was not undertaken following NICE
advice that exhaustive searching on every
guideline review topic is not practical or effici-
ent (Mason et al., 2002).
Titles and abstracts were retrieved and reviewed
by two researchers for eligibility. Relevant papers
were ordered. Study appraisal andmethodological
quality were assessed using checklists designed
with assistance from the Centre for Statistics in
Medicine at Oxford University.
Data was abstracted by a single reviewer and
evidence tables compiled. All included articles
were subject to quality assessment by a second
reviewer. Any discrepancies between reviewers
were resolved by discussion. Where needed, a
third reviewer assisted with decisions on the
inclusion or exclusion of a study. Full details of
data abstraction, sifting, and reviewing processes
can be found inRoyal College of Nursing (2005).
DATA SYNTHESIS
Quantitative analysis was considered inappro-
priate for this review, as advised by methodolo-
gical experts. Summary statistics of significance
are reported in the evidence tables in Royal
College of Nursing (2005). All possible medica-
tions were considered in the review however,
only those currently licensed for use in the
UK will be reported here.
EVIDENCE SUMMARY
From 153 studies identified in the initial sift, 20
papers detailing phase III randomised controlled
trials were retrieved. One was excluded because
Box 1. Risk of adverse cardiac events
Although rare, life threatening cardiac disturbances may be induced by antipsychotic drugs when used for rapid tranquilisation. In
some cases these drugs may affect cardiac ventricular repolarisation (the QT interval). A number of factors such as physical exertion
and stress may also impact on the QT interval.
QTc interval is a useful, if somewhat imprecise indicator of the risk of cardiac events. Prolongation can be congenital or acquired.
Service users who already have prolonged QTc are at risk of developing an arrhythmia when given drugs which further lengthen the QT
interval. Service users with torsades de pointes, left ventricular dysfunction or hypertrophy and liver disease are at an increased risk
(Day et al., 1993). Additional risk factors also include diuretics or other arrhythmogenic drugs. Females tend to have a longer QT
interval on average than men, which therefore increases their risk of torsades de pointes (Rautaharju et al., 1992; Makkar et al.,
1993).
The relationship between antipsychotics, ventricular tachycardia and sudden cardiac death is not straight forward. QT prolongation
and resulting arrhythmias are generally dose related (Drici et al., 1998; Warner et al., 1996; Reilly, 2000; Ray et al., 2001). It is also
important to note that several case reports of sudden death involved agitated service users who were subject only to physical
interventions. Other factors implicated in the increased risk of arrhythmia include the use of the illicit drugs such as ecstasy (Drake &
Broadhurst, 1996) and cocaine (Pereira et al., 1997).
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it was already included in a specific medications
systematic review which forms part of the
evidence base of this review. One of these stud-
ies reported on two different trials (Garza-
Trevino et al., 1989). Unless otherwise stated,
all studies considered the intramuscular (i/m)
route. Some studies switched to oral formula-
tions after the first 24hrs; where this occurs
it is indicated in the evidence tables (Royal
College of Nursing, 2005).
Seven of nine systematic reviews identified
proved relevant to the research question.
Three of these had similar aims to the NICE
evidence review (Royal College of Psychia-
trists, 1998; National Collaborating Centre for
Mental Health, 2002; Broadstock, 2001). Stud-
ies included in these reviews were indepen-
dently assessed and those not excluded form
part of the evidence base for the review. Only
systematic reviews to phase III randomised con-
trolled trials are included.
The other four systematic reviews looked
at specific medications for rapid tranquillisation.
Dual diagnosis was not considered in the review.
Appraisal of methodological quality
Common methodological shortcomings were:
* Inappropriately small sample sizes (number
needed to treat (NNT) not always stated or
sufficient)
* Participants not always sufficiently agitated
to require rapid tranquillisation
* Outcome measures not always sufficiently
defined
* Intention to treat analysis not always clearly
described
* Statistical measures, odds ratio (OR), relative
risk (RR) and confidence intervals (CI) not
clearly reported
* Different comparator medications, doses and
outcomes were reported (e.g. sleep as both a
desired endpoint and as an adverse effect)
* Poorly defined terminology which further
complicated any comparison
* Follow-up periods different across studies
* Most studies did not report their method
of randomisation nor how they ensured
blinding/lack of bias.
FINDINGS
Clotiapine, ziprasidone, loxapine and thiothix-
ene will not be discussed as they are not licensed
in the UK. Neither will droperidol as it was
voluntarily withdrawn by the manufacturer,
Janssen-Cilag Ltd, from the end of March
2001, amid concerns over the medication’s
safety as an oral treatment for chronic condi-
tions. Cost effectiveness of production resulted
in other forms of the medication also being
withdrawn. It is now unavailable in the UK
for rapid tranquillisation.
Conventional antipsychotics
Chlorpromazine
Reschke (1974) compared i/m chlorpromazine
25mg, i/m haloperidol 5mg, 2mg, 1mg, and
i/m placebo. Aggression was significantly more
effectively controlled with i/m haloperidol 5mg
and 2mg compared to i/m haloperidol 1mg, i/m
chlorpromazine 25mg or i/m placebo. More
adverse reactions were noted with haloperidol
(transient hypertension, drowsiness, dry mouth
andmildEPS) than chlorpromazine, although there
was greater somnolence with chlorpromazine.
The study had a very small sample size. Most par-
ticipants in this study were women. Chlorpro-
mazine i/m is no longer considered a suitable
medication for rapid tranquillisation (Royal
College of Psychiatrists, 1997).
Haloperidol
Haloperidol is recommended as the medica-
tion of choice in a number of national guide-
lines (McAllistair-Williams & Ferrier, 2004).
A number of randomised controlled trials
(reported below) consider the effectiveness
and safety of haloperidol in relation to other
medications:
* Olanzapine  Brier et al., 2002; Wright
et al., 2001
* Ziprasidone  Brook et al., 2000
* Loxapine  Tuason, 1986; Fruensgaard et al.,
1977; Paprocki & Versiani, 1977
* Lorazepam  Foster et al., 1997; Battaglia
et al., 1997, Bieniek et al., 1998; Garza-
Trevino et al., 1989
* Midazolam  Wyant et al., 1990.
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Two further trials (Binder & McNiel, 1999;
Dorevitch et al., 1999) evaluated the efficacy
and safety of i/m haloperidol against i/m fluni-
trazepam and i/m molindone. Neither of these
studies showed a significant difference between
haloperidol and the other medication in terms
of effectiveness. Flunitrazepam showed a
slightly quicker reduction in aggression at
30 minutes but this did not reach significance
at 90 minutes on the Overt Agitation Scale
(Yudofsky et al., 1997). Molindone showed
slightly less reduction in symptoms at 3 hours.
Erythema at injection site was slightly more
common for molindone than haloperidol. This
side-effect is not discussed in relation to i/m
flunitrazepam. Both studies had small sample
sizes and neither used objective measures to
evaluate behaviour at baseline. In the study of
molindone there was no adjustment to the
p value to account for the many comparisons
and outcomes (outcomes were not restricted
to rapid tranquillisation). It was also diffi-
cult to assess whether side effects resulted from
the oral phase of the intervention. No firm
conclusion can be reached about the relative
superiority of these medications compared to
haloperidol, although both flunitrazepam and
molindone appear to be reasonably safe and
effective within these trials.
Garza-Trevino et al., (1989) considered i/m
thiothixene in combination with i/m lorazepam
against i/m haloperidol in combination with
i/m phenobarbital (see below for details). All
studies suggest that haloperidol appears to be
a reasonably safe and effective medication for
rapid tranquillisation. Thiothixene is not
licensed for use in the UK.
The SPC for haloperidol (Haldol) has been
updated to include a requirement for baseline
ECG prior to treatment. ECG is recommended
prior to treatment in all patients, especially in
the elderly and patients with a positive personal
or family history of cardiac disease or abnormal
findings on cardiac clinical examination. During
therapy, the need for ECG monitoring (e.g. at
dose escalation) should be assessed on an indi-
vidual basis. Whilst on therapy, the dose should
be reduced if QT is prolonged, and haloperidol
should be discontinued if the QTc exceeds
500 ms. Inevitably, this has clinical implications
for using haloperidol for rapid tranquillisation in
situations where it has not been possible to
obtain an ECG prior to initiating treatment. In
such circumstances the use of haloperidol
would be considered ‘off label’. Prescribing
medicines in this way alters (and probably
increases) the prescriber’s professional respons-
ibility and potential liability.
Zuclopenthixol acetate
A high quality systematic review (Gibson et al.,
2001) looked at the efficacy of zuclopenthixol
acetate for use in emergency psychiatry. The
review concluded that this medication was cur-
rently only justified in terms of clinical (i.e.
expert opinion), rather than research, evidence.
No further studies of zuclopenthixol acetate
were identified by our searches. Reviewers
noted that zuclopenthixol acetate is slow acting
and therefore is normally no longer recom-
mended for rapid tranquillisation. Furthermore,
it has been noted that a number of sudden
deaths and fatal cardiac events have been
reported to the Medicines Control Agency
(MCA) in the UK in relation to zuclopenthixol
acetate (McAllistair-Williams & Ferrier, 2004).
Atypical antipsychotics
Risperidone
One systematic review (Aleman & Kahn, 2001)
looked at the efficacy risperidone. There were
some quality concerns with this review. The re-
view considered this medication’s function for
the management of aggression, but excluded a
study because it looked specifically at violence.
There were additional quality issues underlying
this exclusion. Some attempt was made to
counter the heterogeneity of the studies by car-
rying out analyses of only double-blinded ran-
domised studies and those with similar doses in
order to assess the significance of various meth-
odological differences between the studies. The
reviewers note that risperidone is not available
as an intramuscular preparation for acute use,
which further limits its suitability for an emer-
gency situation. The authors’ conclusions on
the efficacy and appropriateness of risperidone
appear to be overly optimistic in relation to
 NAPICU 2008:4:4357 47
Establishing gold standard approaches to rapid tranquillisation
the evidence base and should, therefore, be
interpreted with caution.
Olanzapine
Two trials (Brier et al., 2002; Wright et al.,
2001  sponsored by Eli Lilly) evaluated i/m
olanzapine against i/m haloperidol and against
i/m placebo. Both studies were large multi-
site, multi-country studies (571 participants in
total). It is unclear whether the participants
actually required rapid tranquillisation since all
gave consent before being included in the
study. Objective measures of behaviour were
used in both studies at baseline (Positive and
Negative Syndrome Scale (PANSS); Kay et al.,
1992). There was no long term follow up
with either study. Wright et al. (2001) found
that both olanzapine and haloperidol were
significantly more effective than placebo in
reducing agitation at 2 and 24 hours in both
studies. At 30 minutes, a dose of 5.0mg,
7.5mg or 10mg was significantly more effective
that placebo. Olanzapine was significantly more
effective than haloperidol in reducing agitation
at 15, 30 and 45 minutes. The group sizes in
Brier et al. (2002) did not allow comparison
with placebo. Acute dystonia was not associated
with olanzapine, but was found in 7% of the
haloperidol group (Wright et al., 2001). Brier
et al. (2002) also found that olanzapine was
not associated with dystonia. There were no
differences between olanzapine, haloperidol
and placebo in terms of hypotension and clinic-
ally relevant changes in the QTc interval (Brier
et al., 2002). On this basis Brier et al. (2002)
suggested that olanzapine has a safer profile
than haloperidol. For a meta-analysis of these
two studies which slightly favours olanzapine
see the NICE schizophrenia guideline (National
Collaborating Centre for Mental Health, 2002).
The manufacturers of olanzapine advise prescri-
bers against the use of olanzapine outside the
SPC recommended dose as severe adverse
effects have been recorded.
Subsequent to the review, a further trial
(Raveendran et al., 2007) evaluated i/m
olanzapine against haloperidol in combination
with promethazine. This trial was conducted
in Vellore, India and is part of the TREC-India
II collaborative group. 300 participants were
randomised and followed up at 15, 30, 60, 120,
240 minutes after administration of medication.
Inter-rata reliability in assessing severity of
violent incidents and rating of outcome measures
of tranquil/asleep was conducted. Patients were
eligible if a relative was available to give consent.
This study focussed on the effectiveness of the
medications to remain effective over time. Olan-
zapine was more likely to calm (as oppose to
sleep) patients within 1 hour, however, the
effects wore off after that time and resulted in
17% more than the haloperidol with prometha-
zine group receiving additional medical assess-
ment. Haloperidol with promethazine was
found to rapidly calm patients with most asleep
and this was maintained over 4 hours. The
authors conclude that in a situation where med-
ical resources are scarce haloperidol with pro-
methazine would be the better option.
However, a sedated patient’s vital signs should
be monitored more closely and this is likely to
impact on nursing and medical resources.
Benzodiazepines
Lorazepam
Two studies compared the benzodiazepine i/m
lorazepam with the conventional anti-psychotic
i/m haloperidol (Foster et al., 1997; Battaglia
et al., 1997). Foster et al. (1997) noted no signi-
ficant difference between the agitation scores for
lorazepam and haloperidol at 1 hour on the Brief
Psychiatric Rating Scale (BPRS; Overall &
Gorham, 1962) but did note a significant differ-
ence in favour of lorazepam at 1 hour on the
Clinical Global Impression scale (CGI; Guy,
1976). Battaglia et al. (1997) noted no significant
difference between haloperidol and lorazepam at
1 hour, based on mean Agitated Behaviour
Scale (ABS; Corrigan, 1989). Battaglia et al.
(1997) and a further study (Garza-Trevino et al.,
1989) considered the efficacy and safety of these
two medications against a combination of halo-
peridol and lorazepam. Battaglia et al. (1997)
noted a significant difference between haloperidol
and combination at 1 hour, based on ABS score
and between lorazepam and the combination
at 1 hour based on ABS score. However, it is
unclear if the combination would have been
superior if the dose of the single agents had
been equivalent to that of the combination.
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Garza-Trevino et al., (1989) found the combina-
tion was more likely to lead to tranquillisation in
30 minutes. Bieniek et al., (1998) only considered
the efficacy and safety of haloperidol against
that of a combination of haloperidol and lora-
zepam. Non-parametric tests indicated that a
greater percentage of participants improved post
60 minutes in the combined group. The studies
had a number of limitations that meant that
meta-analysis was not considered appropriate.
Garza-Trevino et al. (1989) was not double-
blinded, Battaglia et al. (1997) considered sleep
as a desirable endpoint (the other studies did
not) and combination doses were not equivalent
to single medication doses. In terms of efficacy,
no study found the antipsychotic to differ from
the benzodiazepine. However, given the side
effects caused by haloperidol (e.g. dystonia), all
authors suggested that lorazepam might be the
preferred course of treatment.
Midazolam
The study of i/m haloperidol vs i/m midazolam
or i/m sodium amytal (Wyant et al., 1990)
randomly assigned participants to either i/m halo-
peridol 10mg, i/m midazolam 5mg or i/m
sodium amytal 250mg. Over 2 hours i/m sodium
amytal and i/m midazolam proved significantly
more effective than haloperidol in terms of
mean global ratings for motor agitation, but there
was no significant difference in hostility rating.
This study has several limitations: very small sam-
ple size, only single blinded, insufficient data in
the paper, and side effects are not mentioned.
The authors recognise the need for a large
scale future study comparing midazolam with
lorazepam. The study of midazolam used sleep
as a desirable endpoint, making comparisons
with other studies difficult.
Another study considered midazolam and
lorazepam against haloperidol plus prometha-
zine (please see below).
Combination studies
Thiothixene & lorazepam vs haloperidol &
phenobarbital
One study considered the use of i/m thiothix-
ene in combination with i/m lorazepam against
i/m haloperidol in combination with i/m
phenobarbital (Garza-Trevino et al., 1989).
This study was not double-blinded, there
was a very short follow up period (24hr) and
side effects were not described, although the
authors claim that there were few indications
of over-sedation or dystonic reactions. There
appeared to be no difference in effectiveness
between the two groups. The authors argue
therefore that a combination of antipsychotic
and a hypnosedative is a useful intervention
for the management of agitated behaviour. It is
difficult to generalise concerning the effective-
ness and safety of these medication combina-
tions on the basis of only one study given the
various limitations noted above.
Haloperidol plus promethazine (vs lorazepam,
vs midazolam)
One study (TREC Collaborative Group, 2003)
compared i/m haloperidol-promethazine with
i/m midazolam. Clinicians decided doses within
a range of 7.515mg of i/m midazolam and 5mg
of i/m haloperidol plus 2550mg i/m prometh-
azine. More somnolence was noted in the mida-
zolam group. One man suffered respiratory
depression with i/m midazolam 15mg and
recovered after being given (i/v) flumazenil
0.25mg. One woman with epilepsy suffered a
grand mal seizure with i/m haloperidol 5mg
and i/m promethazine 50mg. When ratios of
those either asleep or tranquil at 1 hour are
considered, the study favours midazolam.
However, a larger percentage of these patients
were asleep in the midazolam group than in the
haloperidol and promethazine group (93% com-
pared to 87%). If only those patients who were
tranquil at 1 hour are considered, the treatment
favours haloperidol plus promethazine. No defi-
nitions are provided for tranquil or asleep.
Alexander et al. (2004) compared i/m halo-
peridol and i/m promethazine combined with
i/m lorazepam. Doses were haloperidol 10mg
plus promethazine 2550mg or lorazepam
4mg. Haloperidol i/m plus promethazine i/m
was significantly more likely to induce sleep for
all time periods. Haloperidol i/m plus prometh-
azine i/m also resulted in quicker onset of tran-
quillisation/sleep. Four people in lorazepam
group were never tranquil, One person in the
haloperidol plus promethazine group was never
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tranquil. No adverse reactions were noted with
haloperidol plus promethazine. One person in
the lorazepam group with history of bronchial
asthma complained of moderate worsening of
respiratory difficulty. Another person reported
nausea and dizziness. There was no dystonia.
Sleep was considered the desirable endpoint.
When ratios of those either asleep or tranquil
at 1 hour are considered, the study favours halo-
peridol plus promethazine. However, a larger
percentage of these patients were asleep in the
haloperidol and promethazine group than in
the lorazepam group. If only those patients
who were tranquil at 1 hour are considered,
the treatment favours lorazepam.
Alexander et al. (2004) considered sleep the
primary desirable outcome. The study did, how-
ever, detail numbers asleep and numbers tranquil
at each endpoint. Alexander et al. (2004) argued
that sleep is a safer option for staff, however, no
significant difference in injury rates were noted
with lorazepam, which was less sleep inducing.
Neither study mentioned whether monitor-
ing procedures, e.g. observation, ECG, etc. were
put in place once participants were classified as
asleep. There is disagreement between the stud-
ies as to whether haloperidol plus promethazine
is actually more likely to induce sleep than a ben-
zodiazepine. The studies suggest that haloperidol
plus promethazine may be effective in rapid tran-
quillisation when sleep is a desirable outcome.
However, if tranquil (calm) is the desirable end-
point, lorazepam alone is favoured. Few patients
treated with i/m haloperidol plus i/m prometh-
azine suffered dystonic reactions.
Both studies were large studies of a high meth-
odological quality. However, after consultation
with two independent methodological advisers,
it was decided that meta-analysis would not be
appropriate for the following reasons:
* It is unclear that midazolam and lorazepam
are sufficiently similar clinically to be treated
as a single class.
* The dose used may not be equivalent.
* Different time points were used (TREC
Collaborative Group (2003)  4 hours;
Alexander et al. (2004)  15mins) masking
differences in effect when combined.
* TREC Collaborative Group (2003) took
measurements at 20mins, but not with blinded
raters.
These studies have also been reviewed in a
Cochrane review (Huf et al., 2004), which con-
cluded midazolam has a faster onset than loraze-
pam, however both benzodiazepines have
potential to cause respiratory depression. There-
fore Huf et al. (2004) favoured haloperidol with
promethazine as the combination of choice for
rapid tranquillisation. Outcome measure was
tranquil or asleep. The studies were conducted
in Rio, Brazil and Vellore, India. Subsequent to
the NICE review (NICE, 2005) another trial
conducted by the same group in Rio compared
haloperidol with promethazine with haloperidol
alone. This study found no evidence of benefit
and significant evidence of harm in administering
haloperidol alone (Huf et al., 2007).
The NICE guideline evidence review con-
cluded that:
* There appear to be no conclusive benefits in
terms of effectiveness of one antipsychotic
over another, of antipsychotics over benzo-
diazepines or of combination medications
over single medication regimes for rapid
tranquillisation.
* The body of evidence suggests rapid tran-
quillisation as an intervention for the short-
term management of disturbed/violent
behaviour is both reasonably effective and
reasonably safe. This evidence suggests that
both benzodiazepines and antipsychotics
appear to be effective and reasonably safe
for use in rapid tranquillisation.
* It is not possible to determine the safety or
effectiveness of medications other than anti-
psychotics and benzodiazepines for rapid
tranquillisation.
For a detailed account of the NICE guideline
review studies considered please see the evid-
ence tables in the full version of the Violence
guideline, appendix 2 (NICE, 2005).
Rapid tranquillisation and
clinical practice
The GDG used formal consensus techniques to
generate clinically relevant recommendations.
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This was based on the available evidence at the
time of the review and on clinical expertise.
The guideline has 35 recommendations for the
practice of rapid tranquillisation in the context
of the short term management of disturbed/
violent inpatients. The recommendations cover
the use of both oral and parenteral medications,
safety and aftercare of the service user. For a full
list of the recommendations for clinical practice
see full and short form versions of the violence
guideline (NICE, 2005).
Only key recommendations pertinent to the
focus of this paper are reported and are listed
in Table 1 alongside indications, contra indica-
tions and restrictions for use.
DISCUSSION
The work of the TREC groups have substan-
tially added to the evidence base of rapid
tranquillisation, particularly as they have con-
ducted high quality studies that are pragmatic-
ally conducted in the real world of rapid
tranquillisation. The function of a guideline is
to take that evidence and translate it into clinical
practice. The NICE guideline (NICE, 2005)
endeavoured to provide clinicians with recom-
mendations to facilitate their treatment options
in the circumstances of each individual event.
We suggest that for rapid tranquillisation, fast
and safe medication treatment that eliminates
the threat of violence with the primary aim of
calming a service user to enable the use of psy-
chosocial techniques is optimal. This should be
balanced against the continued threat of viol-
ence/harm to self and others. It was the aim of
the guideline development group (GDG) to
promote pharmacological interventions which
calmed rather than sedated the service user to
enable psychosocial intervention. Haloperidol
with promethazine is fast and effective at tran-
quillising or sedating the service user (Huf
et al., 2004; 2007). However, this combination
has been tested outside the UK context. The
GDG considered this to be less clinically relev-
ant to the UK context because the primary out-
come of the studies had sleep as the endpoint.
In the UK setting, the primary objective is to
calm. Haloperidol with midazolam has been
found to be effective and fast. However, mida-
zolam is considered to have stronger respiratory
effects than lorazepam (Huf et al., 2004).
Subsequent to publication of the guideline, the
MHRA issued guidance which updated the SPC
for haloperidol to indicate that all patients receiv-
ing this drug should have an ECG prior to initi-
ation. It therefore cannot be assumed that
haloperidol is safe in all patients. Haloperidol
with lorazepam was the combination of choice
in the guideline for service users experiencing
psychosis. The use of haloperidol as a medication
of first choice for rapid tranquillisation should
now be reconsidered in the light of the need for
ECG monitoring. The results of the recent olan-
zapine vs haloperidol with promethazine trial
suggest that olanzapine can be effective with ser-
vice users with moderate disturbance in line
with the current recommendation in the guide-
line. Table 1 presents a summary of indications
and contra-indications for use of the principle
rapid tranquillisation medications, alongside rel-
evant key recommendations from the NICE
guideline and medication restrictions.
The outcomes measured in the TREC stud-
ies do not clearly separate tranqillising from
sleep. In taking into account the guideline
recommendations in Table 1, the aim of the
GDG was to promote the use of pharmacolo-
gical treatments to calm the patient to the
extent that other psychosocial techniques could
be employed to foster the ongoing treatment
and care of the patient.
The guideline recommends the use of anti-
muscarinic agent, such as procyclidine or benza-
tropine to reduce the extrapyramidal side effects
of haloperidol. Huf et al. (2007) suggested that
the routine use of a more sedative drug with
anti-cholinergic properties (promethazine) has
advantages.
The key points of this debate are:
* The service user outcomes-sleep or a state of
calm
* The effective and safe elimination of the
threat of violence, and the reduction of
agitation and aggression
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* The initial treatment of psychosis if present
* Minimal risk of drug reactions or side effects
to the service user
* The continuance of other psychosocial tech-
niques.
The gold standard for rapid tranquillisation
has not been found. The TREC trials in
Rio and Vellore are of a high quality. Such
trials on this important area of care are difficult
due to ethical issues. Most trial participants
were brought to hospital without relatives and
were unable to give their consent, although
information on the study was provided to the
participant after the acute episode (Huf et al.,
2007). However, in the Raveendran et al.
(2007) trial patients were entered into the study
only if a relative was able to consent.
The clinician needs a hierarchy of options to
be able to respond to the individual service user
within the context of other support that may be
provided within a particular setting.
CONCLUSIONS & CLINICAL
IMPLICATIONS
Overall there is a lack of high quality clinical trial
evidence surrounding the drugs used for rapid
tranquillisation and their safety within UK set-
tings. A body of evidence is developing outside
the UK context. Its relevance to the UK context
needs to be established. Increasing concerns
about the safety of haloperidol and other antipsy-
chotics should be taken into account when new
guidelines are developed. In the meantime, clin-
icians need to consider prescribing from a range
of options which will inevitably be influenced
by the ability to safely monitor the service user’s
cardiac and respiratory function.
Further research is urgently needed in order
to establish a gold standard medicine regime
for rapid tranquilisation in the UK. The current
NICE guideline is due for an update in 2009.
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GLOSSARY
Anaesthetised: A state of narcosis (uncon-
sciousness), analgesia (lack of awareness of
pain) and muscle relaxation. It is one stage
beyond deep sedation. It implies loss of air-
way control and protective reflexes, and
requires the constant attention of trained per-
sonnel to keep the patient safe. There is
normally no verbal contact.
Calming: A reduction of anxiety/agitation.
Deep sedation: a reduction of consciousness
and motor and sensory activity, where verbal
contact is progressively lost and then (danger-
ously) excessive airway control and protective
reflexes are lost.
Dystonia: A slow movement or extended
spasm in a group of muscles.
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Light sedation: A state of rest and reduction
of psychological activity, but verbal contact is
maintained.
Rapid tranquillisation (also called urgent
sedation): The use of medication to calm/
lightly sedate the service user and reduce the
risk to self and/or others. The aim is to
achieve an optimal reduction in agitation and
aggression thereby allowing a thorough psy-
chiatric evaluation to take place whilst allow-
ing comprehension and response to spoken
messages throughout.
Sleep: A condition of body and mind such as
that which normally recurs for several hours
every night, in which the nervous system
is inactive, the eyes closed, the postural
muscles relaxed and consciousness practically
suspended.
Violence: The use of physical force which is
intended to hurt or injure another person
(Wright et al., 2002).
WMD: Weighted mean difference
Of all these terms ‘sleep’ is the one with the
greatest terminological inexactitude. For the
purpose of this paper we have adopted this
definition from the Oxford English Dictionary.
However because of its inexactitude, we have
generally avoided using the term in the violence
guideline.
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